Press Room

February 17, 2015

Lifetime’s “The Balancing Act” Show for Women to Discuss the Breast Cancer IndexSM Molecular Test

Lifetime’s “The Balancing Act” Show for Women to Discuss the Breast Cancer IndexSM Molecular Test

Airing February 18 & 25, the program will focus on understanding unmet needs in the management of early stage, estrogen receptor-positive breast cancer after patients have completed five years of treatment, and how the BCI molecular test can help inform decision-making beyond five years

WHAT: Lifetime’s “The Balancing Act” will feature a discussion about important developments in the management of early stage, estrogen-receptor positive (ER+) breast cancer, including understanding the risk of recurrence beyond year five, side-effects of long-term hormonal drugs, and how to create a more personalized treatment plan with the Breast Cancer Index (BCI). BCI is a gene expression-based test that quantifies risk of breast cancer recurrence and predicts which patients have a high likelihood of benefitting from extended adjuvant endocrine therapy. BCI testing is performed on a patients’ tumor sample and provides valuable patient-specific information.

WHO: The program will feature Dr. Ann Stroh, D.O., a Colorado-based medical oncologist who specializes in breast cancer care and has integrated BCI in her practice and Dr. Catherine Schnabel, Ph.D., Senior Vice President of Research and Development at Biotheranostics, developer of BCI

WHY: Breast cancer is not a five-year disease, as more than half of recurrences of ER+ breast cancer occur beyond five years after diagnosis, referred to as “late recurrence.” BCI is the only commercially available molecular test that quantifies the risk of late breast cancer recurrence and provides predictive information about which patients are likely to benefit from extended endocrine therapy, versus those who are not likely to benefit and may avoid drug treatment and side effects that could impact their health and quality of life. About 70 percent of breast cancers are ER+ (cancer grows in response to estrogen). After initial treatment, patients often receive up to 10 years of endocrine therapy. However, only 3-5 percent of patients benefit from extending therapy beyond year five, and extended endocrine treatment is associated with significant side effects. BCI offers physicians and patients additional information for more confidence and peace of mind with decisions about whether to extend endocrine treatment beyond five years.

DETAILS: “The Balancing Act” segment will air Feb. 18 and Feb. 25 at 7:30 a.m. (EST/PST) on Lifetime.

ABOUT: Biotheranostics, Inc., is a leader in helping physicians improve the care and management of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. For more information, visit www.biotheranostics.com or www.AnswersBeyond5.com. Follow BCI on Twitter at @AnswersByond5.